Tags : BRAF-Mutant Metastatic Colorectal Cancer


Array Biopharma Reports Results of Triplet Combination Therapy in P-III

Shots: The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib), Mektovi (binimetinib) & Erbitux (cetuximab) in patients with BRAF mutant mCRC P-III BEACON CRC trial results: mOS 15.3 mos.; mPFS 8 mos.; ORR 48%; well-tolerated with no toxicities, will be presented at ASCO 2019 Braftovi (encorafenib), Mektovi (binimetinib), Erbitux […]Read More